InsidersTradesSigma
Follow the 리메드 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 리메드 has logged 9 reports. Market capitalisation: €82.2bn. The latest transaction was disclosed on 4 May 2026 (Other). Among the most active insiders: 이근용. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
9 of 9 declarations
리메드 活跃于医疗保健和制药领域，在 XKRX 市场上市。该公司专注于开发创新的医疗保健解决方案。